Last June, Guilford-based Bioasis struck an agreement to license it s xB3 platform technology to the research giant Chiesi Group for the development of drugs targeting lysosomal storage disorders, which are inherited diseases caused by an abnormal build-up of toxic material in the body’s cells due to enzyme deficiencies.
Following is an interview with Bioasis Technologies CEO Deborah Rathjen.